Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any ...